[A19-40] Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2019
Project no.:
A19-40
Commission:
Commission awarded on 30.04.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Mental and emotional wellbeing
Within the overall therapeutic strategy in adults with at least moderate-severity ADHS and symptoms since childhood
Added benefit not proven due to a lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2019-10-17 A G-BA decision was published.